亚太地区晚期前列腺癌管理:APCCC 2017共识的实地考量
亚太晚期前列腺癌共识会议汇集15国20位专家,讨论2017 APCCC共识在亚太的实际应用。会议指出遗传环境差异可能增加亚洲男性多西他赛毒性,且新型内分泌药物因经济原因可及性有限,强调成本与可及性是治疗决策关键因素。
要点
- 亚太地区遗传与环境差异可能影响晚期前列腺癌管理。
- 亚洲转移性去势敏感前列腺癌患者多西他赛毒性可能增加。
- 新型雄激素受体靶向药物在亚太可及性因经济原因非常有限。
核心结论
- 成本与治疗可及性是影响亚太地区晚期前列腺癌治疗决策的关键因素。
- 亚太地区需协作开展相关研究并收集评估亚太人群数据。
- 多学科团队治疗规划、具备专业知识的临床医生提供最佳实践护理以及患者信息与支持对知情选择至关重要。
研究设计与样本
- 亚太晚期前列腺癌共识会议(APAC APCCC 2018)汇集来自15个亚太国家的20位专家,讨论2017年圣加仑第二届APCCC共识声明的实际应用。
主要发现
- 遗传、环境、生活方式、饮食和文化差异可能影响亚太地区晚期前列腺癌管理。
- 考虑到APCCC 2017强烈推荐转移性去势敏感前列腺癌 upfront 多西他赛,专家组注意到亚洲男性接受多西他赛可能毒性增加,影响该推荐在亚太地区的应用。
- 雄激素受体靶向药物在亚洲转移性去势抵抗前列腺癌男性中耐受性良好,但因经济原因区域可及性非常有限。
- 较低成本/较旧的治疗和技术可能是一种选择,但文化及患者或医生偏好问题意味着这些不一定总可接受。
- 仿制药可在一些国家降低成本,但对低收入患者或社区费用仍可能过高。
关键数值与推荐
- APCCC 2017强烈推荐转移性去势敏感前列腺癌使用upfront多西他赛。
临床怎么用
- 在亚太地区应用APCCC共识时应考虑亚洲男性多西他赛毒性可能增加。
- 治疗决策需结合成本与可及性,并考虑文化及患者/医生偏好。
- 采用多学科团队方法制定治疗计划与护理。
- 临床医生应具备适当专业知识以提供最佳实践护理。
- 重视患者信息与支持以促进知情选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). FINDINGS: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. CONCLUSIONS: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.
引用
- Chiong E, Murphy DG, Akaza H, et al. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU Int. 2018. PMID: 30019467. doi:10.1111/bju.14489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。